SCHEMBL23218713

SCHEMBL23218713

CCOC(=O)Cc1ccccc1OCc1coc2c(C3CC3)cc(Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TBXAS1 P24557 1/20 0.38
CFD P00746 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
PTGDR Q13258 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852542 1.00 PTGDR2 (0.39) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL23218272 0.85 MEN1 (0.35) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL29853140 0.85 MEN1 (0.35) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL29591267 0.85 TBXAS1 (0.40) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL23219098 0.85 TBXAS1 (0.40) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL23229148 0.84 MEN1 (0.36) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL29852993 0.84 PTGER4 (0.38) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL23218917 0.84 PTGER4 (0.38) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL23218334 0.84 ALOX15 (0.37) PTGDR2MEN1KMT2ATBXAS1CFD
SCHEMBL29593177 0.84 ALOX15 (0.37) PTGDR2MEN1KMT2ATBXAS1CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTGDR2 484/4885MEN1 1819/4885KMT2A 4445/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTGDR2 976/4885MEN1 548/4885KMT2A 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.